miércoles, 22 de abril de 2015

Transmission of Hepatitis C Virus among Prisoners, Australia, 2005–2012 - Volume 21, Number 5—May 2015 - Emerging Infectious Disease journal - CDC

FULL-TEXT ►

Transmission of Hepatitis C Virus among Prisoners, Australia, 2005–2012 - Volume 21, Number 5—May 2015 - Emerging Infectious Disease journal - CDC





Volume 21, Number 5—May 2015

Research

Transmission of Hepatitis C Virus among Prisoners, Australia, 2005–2012

Neil Arvin Bretaña, Lies Boelen, Rowena Bull, Suzy Teutsch, Peter A. White, Andrew R. Lloyd, Fabio LucianiComments to Author , and on behalf of the HITS-p investigators
Author affiliations: The University of New South Wales, Sydney, New South Wales, Australia (N.A. Bretaña, L. Boelen, R. Bull, S. Teutsch, P.A. White, A.R. Lloyd, F. Luciani)Imperial College London, London, UK (L. Boelen)

Abstract

Hepatitis C virus (HCV) is predominantly transmitted between persons who inject drugs. For this population, global prevalence of HCV infection is high and incarceration is common and an independent risk factor for HCV acquisition. To explore HCV transmission dynamics in incarcerated populations, we integrated virus sequences with risk behavior and spatiotemporal data and analyzed transmission clusters among prisoners in Australia. We detected 3 clusters of recent HCV transmission consisting of 4 likely in-custody transmission events involving source/recipient pairs located in the same prison at the same time. Of these 4 events, 3 were associated with drug injecting and equipment sharing. Despite a large population of prisoners with chronic HCV, recent transmission events were identified in the prison setting. This ongoing HCV transmission among high-risk prisoners argues for expansion of prevention programs to reduce HCV transmission in prisons.
Hepatitis C virus (HCV) is a blood-borne virus that infects 3–4 million persons each year (1). In industrialized countries, transmission of HCV is largely attributed to injection drug use (2). The association between injection drug use, HCV infection, and imprisonment is very close (3). People who inject drugs (PWID) account for a large proportion of the incarcerated population in the United States, Canada, Europe, and Australia (47), and injection drug use is prevalent during incarceration (8,9). Globally, the prevalence of HCV infection among prisoners is ≈30% (10,11). A meta-analysis of 30 studies conducted in different countries revealed a clear association between the prevalence of HCV infection among prisoners and a history of injection drug use (6).
A recent meta-analysis of HCV incidence studies among prisoners revealed a mean incidence of 16.4 (95% CI 0.8–32.1) cases per 100 person-years (11). We recently documented incidence of 14.1 (95% CI 10.0–19.3) cases per 100 person-years in 37 prisons in New South Wales (NSW), Australia, and identified recent injection drug use and Aboriginal and Torre Strait Islander descent as independent risk factors for HCV seroconversion (12). This analysis also identified high prevalence of injection drug use and sharing of injecting equipment in prisons (12). Furthermore, 13 incident cases were identified in a subcohort of 114 prisoners continuously imprisoned (i.e., without release to the community) during the study period (incidence 10.3 cases/100 person-years).
Prisons can be regarded as an enclosed network of facilities within which prisoners are frequently moved. In NSW, prisoners are often transferred between prisons (e.g., because of changes in prisoner security classifications) and temporarily moved for brief periods (e.g., to go to court or obtain medical treatment). In addition, prison sentences in Australia are typically short (average 7–9 months), but reincarceration rates are high (13).
The HCV genome evolves rapidly by mutations caused by highly error-prone replication mechanisms, which generate a swarm of constantly evolving variants (quasispecies) during every infection (14). HCV is classified into 7 genotypes and 67 subtypes (15). At the nucleotide level, each virus subtype differs by up to 25% and genotypes differ by up to 33% (16). The hypervariable region (HVR) of the HCV genome is the most variable; hence, this region is commonly used in molecular epidemiologic studies to detect clusters of persons infected via recent transmission events (17). We used sequences covering envelope (E) 1 and partial E2 (HVR1).
Acute HCV infection is largely asymptomatic; hence, the precise timing and source of transmission are usually unknown. Accordingly, virus sequencing and phylogenetic analysis have been used to reconstruct probable transmission chains from prevalent cases (1820). Although broad linkages between HCV-infected persons have been demonstrated, previous efforts to identify probable transmission pairs among infected persons by using a combination of social network information and phylogenetic analysis techniques suggested that social and genetic distances were only weakly associated (21). By contrast, a recent report from a study that used this same approach among both prevalent and incident (newly infected) case-patients, identified probable clusters evidenced by proximity of social network and clustering analysis of core HCV sequences in a community-based cohort of PWID (22).
Our study used an integrated analysis of molecular, epidemiologic, and spatiotemporal data from a well-characterized cohort of longitudinally followed PWID. We used incident case detection in prisons to identify clusters of recent HCV transmission.

Mr. Bretaña is a PhD candidate in the Inflammation and Infection Research Centre, School of Medical Sciences, The University of New South Wales, Sydney, Australia. His research interests are phylogenetics, epidemiology, and computational modeling of hepatitis C virus transmission.

Acknowledgments

The HITS-p investigators include Kate Dolan, Paul Haber, William Rawlinson, Carla Treloar, Greg Dore, Lisa Maher, and authors Andrew Lloyd and Fabio Luciani.
This work was supported by grants from National Health and Medical Research Council of Australia including NSW Health, Justice Health, and Corrective Services NSW as partners (grant nos. 222887 and 1016351); and by a National Health and Medical Research Council of Australia Practitioner Fellowship (grant no. 1043067 to A.L.)

References

  1. Kretzer IFdo Livramento Ada Cunha JGoncalves STosin ISpada CHepatitis C worldwide and in Brazil: silent epidemic—data on disease including incidence, transmission, prevention, and treatment. The Scientific World Journal. 2014;2014: article ID 827849. DOI
  2. Shepard CWFinelli LAlter MJGlobal epidemiology of hepatitis C virus infection. Lancet Infect Dis2005;5:55867DOIPubMed
  3. Hunt DRSaab SViral hepatitis in incarcerated adults: a medical and public health concern. Am J Gastroenterol2009;104:102431 .DOIPubMed
  4. Harrison PMBeck AJ. Prisoners in 2005. Bureau of Justice Statistics Bulletin [cited 2013 Oct 24]. http://www.bjs.gov/content/pub/pdf/p05.pdf
  5. Government of Canada. Corrections and conditional release statistical overview [cited 2013 Oct 24].http://publications.gc.ca/collections/Collection/PS4-12-2004E.pdf
  6. Vescio MFLongo BBabudieri SStarnini GCarbonara SRezza GCorrelates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Community Health2008;62:30513DOIPubMed
  7. Butler TMThe L2001 New South Wales inmate health survey [cited 2013 Nov 1].http://www.nobars.org.au/downloads/Inmate_Health_Survey_2001.pdf
  8. Kinner SAJenkinson RGouillou MMilloy MJHigh-risk drug-use practices among a large sample of Australian prisoners. Drug Alcohol Depend.2012;126:15660DOIPubMed
  9. Pollini RAAlvelais JGallardo MVera ALozada RMagis-Rodriquez CThe harm inside: injection during incarceration among male injection drug users in Tijuana, Mexico. Drug Alcohol Depend2009;103:528DOIPubMed
  10. Fazel SBaillargeon JThe health of prisoners. Lancet2011;377:95665DOIPubMed
  11. Larney SKopinski HBeckwith CGZaller NDJarlais DDHagan HIncidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology2013;58:121524DOIPubMed
  12. Luciani FBretana NATeutsch SAmin JTopp LDore GJA prospective study of hepatitis C incidence in Australian prisoners. Addiction.2014;109:1695706DOIPubMed
  13. Payne J. Recidivism in Australia: findings and future research [cited 4 Nov 2013]. http://www.aic.gov.au/documents/0/6/B/%7B06BA8B79-E747-413E-A263-72FA37E42F6F%7Drpp80.pdf
  14. Bull RALuciani FMcElroy KGaudieri SPham STChopra ASequential bottlenecks drive viral evolution in early acute hepatitis C virus infection.PLoS Pathog2011;7:e1002243DOIPubMed
  15. Smith DBBukh JKuiken CMuerhoff ASRice CMStapleton JTExpanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology2014;59:31827DOIPubMed
  16. Simmonds PBukh JCombet CDeleage GEnomoto NFeinstone SConsensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology2005;42:96273 . DOIPubMed
  17. Jacka BLamoury FSimmonds PDore GJGrebely JApplegate TSequencing of the hepatitis C virus: a systematic review. PLoS ONE.2013;8:e67073DOIPubMed
  18. Féray CBouscaillou JFalissard BMohamed MKArafa NBakr IA novel method to identify routes of hepatitis C virus transmission. PLoS ONE.2014;9:e86098DOIPubMed
  19. Matthews GVPham STHellard MGrebely JZhang LOon APatterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C. Clin Infect Dis2011;52:80311DOIPubMed
  20. Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. Hepatology2014;60:157180 Jacka B andApplegate T and Krajden M and Olmstead A and Harrigan PR and Marshall BDDOIPubMed
  21. Aitken CKMcCaw RFBowden DSTracy SLKelsall JGHiggs PGMolecular epidemiology of hepatitis C virus in a social network of injection drug users. J Infect Dis2004;190:158695DOIPubMed
  22. Sacks-Davis RDaraganova GAitken CHiggs PTracy LBowden SHepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugs. PLoS ONE2012;7:e47335DOIPubMed
  23. Dolan KTeutsch SScheuer NLevy MRawlinson WKaldor JIncidence and risk for acute hepatitis C infection during imprisonment in Australia.Eur J Epidemiol2010;25:1438DOIPubMed
  24. Teutsch SLuciani FScheuer NMcCredie LHosseiny PRawlinson WIncidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health2010;10:633DOIPubMed
  25. Page-Shafer KPappalardo BLTobler LHPhelps BHEdlin BRMoss ARTesting strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol2008;46:499506DOIPubMed
  26. Pham STBull RABennett JMRawlinson WDDore GJLloyd ARFrequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology2010;52:156472DOIPubMed
  27. Tamura KPeterson DPeterson NStecher GNei MKumar SMEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol2011;28:27319DOIPubMed
  28. Darriba DTTaboada GLDoallo RPosada D. jModelTest 2: more models, new heuristics and parallel computing. Nat Methods. 2012.9:772.
  29. Guindon SGA simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol2003;52:696704 Gascuel O.DOIPubMed
  30. Prosperi MCCiccozzi MFanti ISaladini FPecorari MBorghi VA novel methodology for large-scale phylogeny partition. Nat Commun.2011;2:321.
  31. Pilon RLeonard LKim JVallee DDe Rubeis EJolly AMTransmission patterns of HIV and hepatitis C virus among networks of people who inject drugs. PLoS ONE2011;6:e22245DOIPubMed
  32. Hope VDHickman MNgui SLJones STelfer MBizzarri MMeasuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. J Viral Hepat2011;18:26270DOIPubMed
  33. The University of New South Wales. HIV/AIDS, viral hepatitis and sexually transmissible infections. In: 2009 annual surveillance report [cited 2014 Sep 2]. http://kirby.unsw.edu.au/sites/default/files/hiv/resources/2009AnnualSurvReport.pdf
  34. Butler TPapanastasiou C. National prison entrants’ bloodborne virus and risk behaviour survey 2004 and 2007 [cited 2014 Oct 20].http://ndri.curtin.edu.au/local/docs/pdf/publications/R223.pdf
  35. Thomas DLGlobal control of hepatitis C: where challenge meets opportunity. Nat Med2013;19:8508DOIPubMed
  36. Paternoster DMSantarossa CGrella PPalu GBaldo VBoccagni PViral load in HCV RNA–positive pregnant women. Am J Gastroenterol.2001;96:27514DOIPubMed
  37. Ruiz-Extremera AMunoz-Gamez JASalmeron-Ruiz MAde Rueda PMQuiles-Perez RGila-Medina AGenetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology2011;53:18308.DOIPubMed
  38. White BDore GJLloyd ARRawlinson WDMaher LOpioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study. Med J Aust2014;201:3269DOIPubMed
  39. Palmateer NKimber JHickman MHutchinson SRhodes TGoldberg DEvidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction.2010;105:84459DOIPubMed
  40. Turner KMHutchinson SVickerman PHope VCraine NPalmateer NThe impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction2011;106:197888DOIPubMed

Figures

Tables

Technical Appendix

Suggested citation for this article: Bretaña NA, Boelen L, Bull R, Teutsch S, White PA, Lloyd AR, et al. Transmission of hepatitis C virus among prisoners, Australia, 2005–2012. Emerg Infect Dis. 2015 May [date cited]. http://dx.doi.org/10.3201/eid2105.141832
DOI: 10.3201/eid2105.141832
1Additional HITS-p investigators are listed at the end of this article.

No hay comentarios:

Publicar un comentario